We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GenomOncology To Enable CompanionDxTM Clinical Cancer Panels
Product News

GenomOncology To Enable CompanionDxTM Clinical Cancer Panels

GenomOncology To Enable CompanionDxTM Clinical Cancer Panels
Product News

GenomOncology To Enable CompanionDxTM Clinical Cancer Panels


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "GenomOncology To Enable CompanionDxTM Clinical Cancer Panels"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GenomOncology announced today that CompanionDxTM has selected the company’s GO Clinical WorkbenchTM to launch a series of next generation sequencing (NGS)-based assays related to cancer. CompanionDxTM will leverage GenomOncology’s GO Clinical Workbench to manage the entire workflow: from raw sequencing data through delivery of an actionable clinical report to the client.

CompanionDx™ is a provider of both personalized pharmacogenomics evaluations and cancer companion diagnostic testing. When used separately or in conjunction, these two types of tests give physicians the resources necessary to develop comprehensive patient treatment profiles, thereby creating more certainty in therapeutic decisions.

David Lasecki, President of CompanionDxTM, commented “As we develop new tests that leverage next generation sequencing, we require a solution that meets our current needs but is scalable over time. GenomOncology’s platform and services will allow us to efficiently add new cancer panels and expand our testing options to best serve our clients.”

The GO Clinical Workbench provides the laboratory with a fully traceable analysis workflow and rules-based decision support tool for the clinical interpretation of somatic mutations.  

“Providing the oncologist with actionable data that is specific to a patient’s tumor in days instead of weeks adds to the medical utility of next generation sequencing,” added Manuel Glynias, President and CEO of GenomOncology. “The convergence of discovery, technology, and therapeutic development has created an unparalleled opportunity to improve clinical outcomes for many patients with cancer.”

Advertisement